You searched for "evidence"

640 results found

Recent advances in the management of castration resistant prostate cancer

Castrate resistant prostate cancer (CRPC) is defined by disease progression despite androgen-deprivation therapy lowering testosterone to castrate levels. It may present as a rise in serum levels of prostate specific antigen (PSA), progression of pre-existing disease, or the appearance of...

Emphysematous pyelonephritis: a review

Introduction Emphysematous pyelonephritis (EPN) is an acute, severe, necrotising, bacterial infection of the renal parenchyma and surrounding tissues, with gas in the renal parenchyma, collecting system or perinephric tissue. Although it is rare, it is potentially life threatening and early...

The role of specialist therapeutic radiographers in the treatment and care of men with prostate cancer

The Statement of Intent: Cancer Strategy for England: 2015-2020 indicates that the number of people diagnosed with cancer each year will continue to grow rapidly due to the ageing population. There is also a requirement to diagnose and offer patients...

Training to be a urologist: how risky is it?

The NHS and urology face challenging times in trying to provide quality patient care efficiently and economically. Urology trainees are experiencing conflicting pressures with a new contract, a challenging on-call system and changing training requirements in an overstretched, centralised service...

Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomised controlled feasibility study

Prostate cancer is the commonest cancer and the second most frequent cause of cancer death in Western men [1]. The recent STAMPEDE data suggests a median survival of just 42.1 months in the control arm of metastatic men [2]. Current...

Stereotactic body radiotherapy for oligometastatic disease secondary to urological cancer

The concept of oligometastatic disease is controversial. The traditional model of cancer, which most of us learnt at medical school, is of a disease which starts confined to an organ, for example the prostate, where it can be cured with...

MRI screening for prostate cancer: a step towards a ‘prostagram’

The UK National Screening Committee has been calling for further research into alternative screening tests for prostate cancer. The committee decided against prostate cancer screening using prostate specific antigen (PSA) testing on the basis that “PSA is still a poor...

Imaging and surveillance in sporadic renal angiomyolipoma: how and when to monitor effectively

Renal angiomyolipoma (AML) are benign tumours, accounting for approximately 2–3% of all renal neoplasms [1]. Seventy percent of renal AMLs are sporadic, and 20–30% are associated with genetic aetiology. They are composed of smooth muscle, blood vessels, and adipose tissue....

UTI and VUR in children with mild antenatal hydronephrosis

This paper describes a retrospective analysis of 760 (608 males, 162 females) patients identified with mild antenatal hydronephrosis (defined by an anteroposterior (AP) pelvic diameter of 7-10mm in the third trimester and persistent postnatal dilation) looking at the incidence of...

Urachal anomalies in children: surgical or conservative treatment?

Urachal anomalies are rare with an incidence of 1:5000-8000 live births. There is still some controversy as to whether to treat them expectantly or surgically with published reports describing malignant changes in adulthood. These authors describe their retrospective series of...

Erectile dysfunction part II: treatment

Introduction The identification of specific risk factors associated with erectile dysfunction (ED) allows patients with mild or moderate ED to undergo a series of lifestyle changes, which may provide enough improvement in the erectile function to avoid pharmacotherapies. Cessation of...

The Royal Marsden: Demystifying the Science Behind Targeted Treatments and Immunotherapies for Prostate, Bladder & Kidney Cancers Study Day

Dr Elaine Vickers will provide an introduction to the science behind a wide variety of targeted therapies and immunotherapies given to people with prostate, bladder and kidney cancer.